Today's press is all over a study published in the August 2007 journal, Diabetes Care. The study collected data on more than 78,000 type2 diabetic patients taking either Avandia (rosigilazone) or Actos (pioglitazone) - drugs used by more than 3 million people in this country. The researchers found that these drugs doubled the risk of heart failure. The average time for heart failure to develop was 24 weeks after starting either one of these drugs. The heart failures occured at even the lowest dosage and among young patients.
Apparently the press has forgotten about similar results published in the same journal in 2005 based on study findings on 25,690 patients. That study clearly suggested that the use of any pharmacological therapy for type2 diabetes dramatically increased the risk of heart failure during the first year after diagnosis.
The FDA has been in negotiation with Big Pharma over "black-box" warnings about heart failure risk on the labels of diabetic drugs for a long time.
To our knowledge, black box warnings for these drugs have yet to be mandated.